Delayed Ga-68 DOTATATE PET/MR for Detecting Liver Metastases in GEP-NETs
Official title: Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver Metastases From Gastroenteropancreatic Neuroendocrine Tumors
Run by First Affiliated Hospital of Fujian Medical University · NCT07898904 · Data updated 2026-11-12
This study tests whether a delayed Ga-68 DOTATATE PET/MR scan can better detect liver metastases in gastroenteropancreatic neuroendocrine tumors compared with the standard Ga-68 DOTATATE PET/CT.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 30 Years to 74 Years |
| Sex | All |
| Enrollment | 46 (estimated) |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Status | Recruiting |
| Started | December 1, 2023 |
| Main results expected | December 31, 2026 |
| Study ends | April 30, 2027 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07898904 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with histologically confirmed well-differentiated GEP-NET and confirmed or suspected liver metastases, and with available comprehensive prior surgical, pathological, and follow-up data.
✕Probably not a fit
Patients without liver metastases or with lesions not better characterized by PET/MR may not experience a diagnostic benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study compares delayed Ga-68 DOTATATE PET/MR with conventional Ga-68 DOTATATE PET/CT for identifying liver metastases in adults with well-differentiated GEP-NETs. It aims to determine diagnostic performance in cases where liver lesions are small or of low avidity. Eligible participants have histologically confirmed GEP-NETs and suspected liver metastases, with comprehensive surgical, pathological, and follow-up data available. The analysis assesses whether PET/MR offers added value over PET/CT for staging and management decisions. The study is conducted at a single institution in Fujian, China and is led by the First Affiliated Hospital of Fujian Medical University.
Why it matters
Potential benefit: If successful, delayed Ga-68 DOTATATE PET/MR could improve detection of liver metastases and inform more accurate treatment planning for GEP-NET patients.
How similar studies have gone: Previous work supports Ga-68 DOTATATE PET/CT as a diagnostic standard, while the added value of delayed PET/MR remains to be clarified in this setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: (a)Histologically confirmed well-differentiated GEP-NETs via biopsy or surgical resection in adults aged 18-80 years,(b) confirmed or suspected liver metastases, as determined by previous imaging studies or PET/CT scans,(c) availability of comprehensive surgical reports, pathological findings, comparative data, and clinical follow-up outcomes for analysis,(d) absence of PET/MR contraindications , with voluntary participation and signed informed consent forms adhering to ethical and research guidelines Exclusion Criteria: (a) unavailability of surgical, pathological or long-term follow-up data; (b) non-compliance with age eligibility criteria or presence of comorbidities compromising protocol adherence
Where it's running
-
Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University
Fuzhou, Fujian, China Recruiting
Study contacts
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: 86-0591-87981618
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Albumin‑bound sirolimus plus long‑acting octreotide for metastatic gastroenteropancreatic neuroendocrine tumors
This test will see if combining albumin‑bound sirolimus with long‑acting octreotide helps people with unresectable or recurrent non‑functional GEP‑NETs who have poor prognostic factors.
-
Preventive Narrative Exposure for PTSD After Cardiac Surgery in the ICU
In adults having cardiopulmonary bypass heart surgery, this trial tests whether an ICU-based narrative exposure intervention helps prevent posttraumatic stress symptoms compared with standard care.
-
A lifetime registry and imaging database for people with heart, kidney, and metabolic conditions
This project will see if creating a long-term clinical and imaging database for adults with heart, kidney, or metabolic conditions can improve prediction of outcomes and guide care.
-
Low-intensity focused ultrasound targeting the globus pallidus to improve movement in Huntington's disease
This trial tests whether different pulse frequencies of low-intensity focused ultrasound (LIFU) aimed at a deep brain target can safely reduce chorea and other motor symptoms in adults with Huntington's disease.
-
Using AI language models to help diagnose and recommend treatments for urologic conditions
This project will test whether three AI language models (ChatGPT, Gemini, DeepSeek) can accurately recognize urologic diseases and suggest diagnoses and treatments from archived hospital records of adult patients.
-
Sequential 225Ac-LNC1011 treatment for metastatic castration-resistant prostate cancer
We'll test whether different doses of a PSMA-targeted alpha therapy called 225Ac-LNC1011 are safe and can shrink tumors in men whose prostate cancer has spread and no longer responds to hormone therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.